Ophthalmology最新文献

{"title":"Human Papillomavirus Infection is Associated with Increased Risk of Glaucoma: Real-World Evidence.","authors":"Wen-Chieh Liao, Yu-Jung Su, Yun-Feng Li, Shao-Wei Lo, Chien-Ying Lee, Hui-Chin Chang, Shuo-Yan Gau","doi":"10.1016/j.ophtha.2025.05.019","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.05.019","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between human papillomavirus (HPV) infection and the subsequent risk of developing glaucoma using real-world data.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Subjects and controls: </strong>Adults aged ≥18 years with a diagnosis of HPV were identified from the TriNetX research network and matched 1:1 to individuals without HPV based on demographics, comorbidities, and healthcare utilization patterns.</p><p><strong>Methods: </strong>Propensity score matching was performed to balance baseline characteristics. Cox proportional hazards models were used to estimate the hazard ratios (HRs) for incident glaucoma. Sensitivity analyses and subgroup stratifications were conducted to assess robustness.</p><p><strong>Main outcome measures: </strong>Incident diagnosis of glaucoma, including open-angle and angle-closure subtypes, following HPV infection.</p><p><strong>Results: </strong>Among 451,288 matched participants, HPV infection was associated with an increased risk of glaucoma (HR: 1.34; 95% CI: 1.28-1.41), with elevated risks observed for both open-angle (HR: 1.33; 95% CI: 1.16-1.52) and angle-closure glaucoma (HR: 1.66; 95% CI: 1.20-2.30). The association was more pronounced in older adults, males, and Asians, and further amplified by comorbidities such as hypertension, diabetes, and myopia. Results were consistent across sensitivity analyses.</p><p><strong>Conclusion: </strong>HPV infection is associated with a higher risk of glaucoma. While these findings highlight a potential need for increased ophthalmologic surveillance in HPV-positive individuals, the possibility of surveillance bias, in which individuals with HPV may receive more frequent healthcare and eye examinations, cannot be excluded. Further studies are warranted to explore causal mechanisms and control for potential confounding.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Corneal Rejuvenation after Transplantation of Cultured Human Corneal Endothelial Cells.","authors":"Shigeru Kinoshita, Morio Ueno, Munetoyo Toda, Kojiro Imai, Yasufumi Tomioka, Kohsaku Numa, Hiroshi Tanaka, Tsutomu Inatomi, Takanori Kameda, Akitaka Tsujikawa, Michio Hagiya, John Bush, Satomi Sakabayashi, Satoshi Teramukai, Junji Hamuro, Chie Sotozono","doi":"10.1016/j.ophtha.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.05.020","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the long-term efficacy of cultured human corneal endothelial cell (CEC) transplantation with rho-associated protein kinase (ROCK) inhibitor for the treatment of corneal endothelial failure (CEF).</p><p><strong>Design: </strong>Prospective observational study.</p><p><strong>Participants: </strong>This study involved 65 patients with corneal endothelial failure treated via cell therapy using cultured allogeneic human CECs (0.2-1.0 x10⁶ cells) supplemented with a ROCK inhibitor injected into the anterior chamber of the eye who were followed up to 10-years postoperative.</p><p><strong>Methods: </strong>At 24-weeks and 1 to 10-years postoperative, corneal transparency, corneal endothelial cell density (CECD), central corneal thickness (CCT), and best-corrected visual acuity (BCVA) on a Landolt C eye chart were recorded. The Kaplan-Meier method was used to estimate the postoperative probability for restoration and persistence of corneal transparency.</p><p><strong>Main outcome measures: </strong>The primary outcome was the corneal restoration and transparency post-surgery. Secondary outcomes were a CEC density exceeding 500 cells/mm² and 1000 cells/mm², corneal thickness of below 630 μm, and an improvement in BCVA equivalent to a decrease of at least 0.2 in logMAR BCVA at 24-weeks and 5-years postoperative.</p><p><strong>Results: </strong>For the primary outcome, the overall success in maintaining corneal transparency at 24-weeks, 5-years, and 10-years postoperative was 98.5% (95% confidence interval [CI], 89.6-99.8%), 93.0% (95% CI, 82.4-97.3%), and 83.7% (95% CI, 54.4-95.0%), respectively. A CEC density of greater than 1000 cells/mm² was achieved in 79.6% (95% CI, 65.7-89.8%), a corneal thickness of below 630 μm was achieved in 85.4% (95% CI, 72.2-93.9%), and a BCVA improvement was achieved in 85.7% (95% CI, 72.8-94.1%) at 5-years postoperative. There were no severe adverse reactions.</p><p><strong>Conclusions: </strong>Cultured human CEC-transplantation therapy was found to be safe and effective over a long-term period for the treatment of CEF.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Gelmi et al.: Survival in patients with uveal melanoma is linked to genetic variation at HERC2 single nucleotide polymorphism rs12913832 (Ophthalmology. 2025;132:299-308).","authors":"Lin Cheng, Yaqiong Liu","doi":"10.1016/j.ophtha.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.04.017","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Maria Chiara Gelmi, Laurien E Houtzagers, Annemijn P A Wierenga, Mieke Versluis, Bastiaan T Heijmans, Gregorius P M Luyten, Peter de Knijff, Marije Te Raa, Rick H de Leeuw, Martine J Jager","doi":"10.1016/j.ophtha.2025.04.018","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.04.018","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Optic Disc Edema in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome with Normal VEGF and Intracranial Pressure.","authors":"Jiaxing Xie, Li Bao, Xue Feng","doi":"10.1016/j.ophtha.2025.04.019","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.04.019","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En Breve","authors":"Sandeep Ravindran PhD","doi":"10.1016/j.ophtha.2025.04.004","DOIUrl":"10.1016/j.ophtha.2025.04.004","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 6","pages":"Pages e1-e2"},"PeriodicalIF":13.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"This Issue at a Glance","authors":"Sandeep Ravindran PhD","doi":"10.1016/j.ophtha.2025.04.005","DOIUrl":"10.1016/j.ophtha.2025.04.005","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 6","pages":"Page 625"},"PeriodicalIF":13.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AT WHAT AGE COULD SCREENING FOR FAMILIAL RETINOBLASTOMA BE STOPPED? REVISED DUTCH RETROSPECTIVE POPULATION BASED COHORT STUDY 1991-2019.","authors":"N A Badalova, M van Hoefen Wijsard, C J Dommering, S L van der Pas, M I Bosscha, A W M Fabius, A C Moll","doi":"10.1016/j.ophtha.2025.05.013","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.05.013","url":null,"abstract":"<p><strong>Objective: </strong>To determine the latest age at which familial retinoblastoma (Rb) is diagnosed in children screened from birth and to assess the implications for optimizing screening protocols.</p><p><strong>Study design: </strong>Retrospective cohort study utilizing nationwide data from the Dutch Rb registry, covering diagnoses from 1991 to 2019.</p><p><strong>Subjects: </strong>The study included 38 children with familial Rb, 28 of whom were completely screened from birth according to a standardized protocol, and 10 were considered incompletely screened.</p><p><strong>Methods: </strong>Data on genetic testing, screening methods, timing, and age at diagnosis were extracted from medical records at Amsterdam UMC.</p><p><strong>Main outcome measures: </strong>Age at diagnosis of familial Rb, categorized by complete versus incomplete screening status.</p><p><strong>Results: </strong>All 28 completely screened children were diagnosed before one year of age, with a median age at diagnosis of 18 days (range: 3-352 days). Sixteen (57.1%) were diagnosed at their first examination within the first month after birth, and 82.1% were diagnosed within the first six months. Among 10 incompletely screened children, the median age at diagnosis was 420 days (range: 59 days to 4.8 years), with more than half diagnosed after one year.</p><p><strong>Conclusion: </strong>Systematic screening of at-risk children from birth, performed by specialized ophthalmologists and followed by examinations under general anesthesia beginning at a few months of age, ensured that all cases of familial Rb were diagnosed within the first year of life. These findings support discontinuing screening sooner than previously advised, for children at low risk (<3%) for familial Rb. The study emphasizes the importance of centralized, standardized protocols to optimize screening durations and reduce healthcare burdens while maintaining safety for at-risk populations.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"期刊一览","authors":"Sandeep Ravindran PhD","doi":"10.1016/j.ophtha.2025.04.006","DOIUrl":"10.1016/j.ophtha.2025.04.006","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 6","pages":"Page e3"},"PeriodicalIF":13.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysis.","authors":"Mathilde Leclercq, Robin Jacquot, Camille Charbonnier, Anne-Claire Desbois, Georgina Maalouf, Sara Touhami, Amine Ghembaza, Fanny Domont, Gaëlle Leroux, Thomas Sales de Gauzy, Adélaïde Toutée, Nicolas Girszyn, Paul Goupillou, Marc Muraine, Christine Fardeau, Ygal Benhamou, Laurent Kodjikian, Patrice Cacoub, Pascal Sève, Bahram Bodaghi, David Saadoun, Julie Gueudry","doi":"10.1016/j.ophtha.2025.05.014","DOIUrl":"https://doi.org/10.1016/j.ophtha.2025.05.014","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy and safety of intra-venous tocilizumab (IV TCZ) and sub-cutaneous tocilizumab (SC TCZ) in the treatment of non-infectious intermediate, posterior and, panuveitis.</p><p><strong>Design: </strong>Multicenter, retrospective, observational study.</p><p><strong>Participants: </strong>Adult patients with non-infectious uveitis treated with TCZ.</p><p><strong>Methods: </strong>Patients received IV TCZ (8 mg/kg/4 weeks; n = 66) or SC TCZ (162 mg/week; n = 70). The decision to introduce TCZ and the administration route were left to the discretion of the clinician.</p><p><strong>Main outcome measures: </strong>Primary outcome: resolution of macular edema at 6 months; secondary outcomes: proportion of patients with treatment success and inactive disease, best-corrected visual acuity (BCVA) change from baseline, median time to relapse or serious adverse events leading to treatment discontinuation, corticosteroid-sparing effect, and adverse events.</p><p><strong>Results: </strong>One hundred thirty-six patients (46% men, median age 51 years, interquartile range 41-65 years) were included. Patients in the IV TCZ group had more severe disease, i.e. more frequent macular edema, worse initial BCVA, more frequent previous anti-TNF alpha failure. A significantly higher proportion of patients in the IV TCZ achieved resolution of macular edema at 6 months (OR 3.96; 95% CI 1.3-12.92; p=0.01). The difference was not significant after 12 months of treatment (OR 2.46; CI 95% 0.30-30.18; p=0.40). The gain in visual acuity after 12 months of treatment was higher in the IV TCZ group, with a 0.19 logMAR gain of BCVA, compared to SC TCZ. At 12 months, 63% of patients in the IV TCZ group and 58% of patients in the SC TCZ group (p=0.80) had an inactive disease and 71% of patients in both groups had treatment success (p=0.99). Median time to relapse or serious adverse events leading to treatment discontinuation were not statistically different between the two groups. A total of 36 patients (26%) had at least one adverse event: 15 patients (23%) in the IV TCZ group and 21 patients (30%) in the SC TCZ group.</p><p><strong>Conclusion: </strong>Although interpretation of the data are limited by their retrospective nature, these data suggest that intravenous tocilizumab may result in faster resolution of uveitic macular edema than does subcutaneous tocilizumab.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":" ","pages":""},"PeriodicalIF":13.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}